Business
Scilex Holding Company Announces Stocking of GLOPERBA® is Underway in all of the Wholesalers with which Scilex has Stocking Arrangements Throughout the U.S.
Stocking of GLOPERBA® is underway in all of the wholesalers with which Scilex has stocking arrangements throughout the U.S and Scilex expects completion of
About this update from Scilex Holding Company
[{"type":"text","content":"Stocking of GLOPERBA® is underway in all of the wholesalers with which Scilex has stocking arrangements throughout the U.S and Scilex expects completion of stocking by Wednesday June 12, 2024.Today, Scilex is launching its third commercial product, GLOPERBA®.Patients will have support of the co-pay savings card for GLOPERBA®.GLOPERBA® is the first and only liquid oral formulation of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.Scilex increased production of GLOPERBA® and product availability under the brand marketed and distributed by Scilex Pharmaceuticals, Inc. for GLOPERBA®. PALO ALTO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced stocking of GLOPERBA® is underway in all of the wholesalers with which Scilex has stocking arrangements throughout the U.S. GLOPERBA®, an FDA-approved prophylactic treatment for painful gout flares in adults in the U.S., is launching today. For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com. About Scilex Holding Company Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout fla...